NCT07348237

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of MK-2828 in Participants With Renal Impairment

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 24 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.

Conditions

• Chronic Kidney Failure
• End-Stage Renal Disease
• Renal Impairment

Interventions

Type	Name	Description
DRUG	MK-2828	Oral administration

Timeline

• Start date: 2026-03-02
• Primary completion: 2026-08-18
• Completion: 2026-08-18
• First posted: 2026-01-16
• Last updated: 2026-04-02

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study